Joseph L Witztum

Joseph L Witztum

University of California, San Diego

H-index: 169

North America-United States

About Joseph L Witztum

Joseph L Witztum, With an exceptional h-index of 169 and a recent h-index of 79 (since 2020), a distinguished researcher at University of California, San Diego, specializes in the field of Atherosclerosis, oxidation, oxidized LDL, oxidized phospholipids, hyperlipidemia.

His recent articles reflect a diverse array of research interests and contributions to the field:

Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia

Oxidized Phospholipid Neutralizing Antibody Ameliorates Pulmonary Fibrosis

Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome

A RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF OLEZARSEN IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME

Oxidized phospholipids in cardiovascular disease

High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction

FRI092 Rationale And Design Of The Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Olezarsen In Patients With Familial Chylomicronemia Syndrome

Joseph L Witztum Information

University

University of California, San Diego

Position

Professor of Medicine

Citations(all)

120791

Citations(since 2020)

25701

Cited By

102818

hIndex(all)

169

hIndex(since 2020)

79

i10Index(all)

469

i10Index(since 2020)

319

Email

University Profile Page

University of California, San Diego

Joseph L Witztum Skills & Research Interests

Atherosclerosis

oxidation

oxidized LDL

oxidized phospholipids

hyperlipidemia

Top articles of Joseph L Witztum

Title

Journal

Author(s)

Publication Date

Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

2024/2/13

Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia

The New England journal of medicine

Veronica J Alexander

Ewa Karwatowska-Prokopczuk

Thomas A Prohaska

Lu Li

Richard S Geary

...

2024/2/1

Oxidized Phospholipid Neutralizing Antibody Ameliorates Pulmonary Fibrosis

E Sajti

W Tang

X Sun

J Witztum

C Glass

2022/5

Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome

The New England Journal of Medicine

Erik SG Stroes

Veronica J Alexander

Ewa Karwatowska-Prokopczuk

Robert A Hegele

Marcello Arca

...

2024/4/7

A RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF OLEZARSEN IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME

Journal of the American College of Cardiology

Erik SG Stroes

Vickie Alexander

Ewa Prokopczuk

Robert Hegele

Marcello Arca

...

2024/4/2

Oxidized phospholipids in cardiovascular disease

Sotirios Tsimikas

Joseph L Witztum

2024/3

High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction

Journal of lipid research

Adam Taleb

Peter Willeit

Shahzada Amir

Thomas Perkmann

Maria Ozsvar Kozma

...

2023/6/1

FRI092 Rationale And Design Of The Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Olezarsen In Patients With Familial Chylomicronemia Syndrome

Journal of the Endocrine Society

Veronica Alexander

Ewa Karwatowska-Prokopczuk

Erik SG Stroes

Christie Ballantyne

Henry N Ginsberg

...

2023/10

APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia

Journal of Clinical Lipidology

Thomas A Prohaska

Veronica J Alexander

Ewa Karwatowska-Prokopczuk

Joseph Tami

Shuting Xia

...

2023/4/27

Effect of APOC3 inhibition with volanesorsen on hepatic steatosis in patients with severe hypertriglyceridemia

Atherosclerosis

T Prohaska

V Alexander

E Karwatowska-Prokopczuk

J Tami

S Xia

...

2023/8/1

Host-derived oxidized phospholipids initiate effector-triggered immunity fostering lethality upon microbial encounter

bioRxiv

Marco Di Gioia

Valentina Poli

Piao J Tan

Roberto Spreafico

Anne Chu

...

2023/11/21

Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial

Journal of clinical lipidology

Joseph L Witztum

Daniel Gaudet

Marcello Arca

Alan Jones

Handrean Soran

...

2023/5/1

On-treatment platelet reactivity through the thromboxane A2 or P2Y12 platelet receptor pathways is not affected by pelacarsen

Journal of Thrombosis and Thrombolysis

Ewa Karwatowska-Prokopczuk

Lu Li

Jun Yang

Joseph L Witztum

Sotirios Tsimikas

2023/8

Therapies and methods to treat tlr2-mediated diseases and disorders

2023/11/9

Apolipoprotein C3 induces inflammasome activation only in its delipidated form

Nature immunology

Cheng-Chieh Hsu

Baohai Shao

Jenny E Kanter

Yi He

Tomas Vaisar

...

2023/3

Rationale and Design of the Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen in Patients with Familial Chylomicronemia Syndrome

Journal of Clinical Lipidology

Ewa Karwatowska-Prokopczuk

Veronica Alexander

Erik SG Stroes

Christie M Ballantyne

Henry N Ginsberg

...

2023/7/1

Antibodies to oxidized phospholipids

2023/11/9

Isoform-independent antibodies to lipoprotein (a)

2023/6/1

Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial …

Journal of Clinical Lipidology

Joseph L Witztum

Daniel Gaudet

Marcello Arca

Alan Jones

Handrean Soran

...

2023/10/13

Effect of pelacarsen on lipoprotein (a) cholesterol and corrected low-density lipoprotein cholesterol

Journal of the American College of Cardiology

Calvin Yeang

Ewa Karwatowska-Prokopczuk

Fei Su

Brian Dinh

Shuting Xia

...

2022/3/22

See List of Professors in Joseph L Witztum University(University of California, San Diego)

Joseph L Witztum FAQs

What is Joseph L Witztum's h-index at University of California, San Diego?

The h-index of Joseph L Witztum has been 79 since 2020 and 169 in total.

What are Joseph L Witztum's top articles?

The articles with the titles of

Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia

Oxidized Phospholipid Neutralizing Antibody Ameliorates Pulmonary Fibrosis

Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome

A RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF OLEZARSEN IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME

Oxidized phospholipids in cardiovascular disease

High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction

FRI092 Rationale And Design Of The Balance Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Olezarsen In Patients With Familial Chylomicronemia Syndrome

...

are the top articles of Joseph L Witztum at University of California, San Diego.

What are Joseph L Witztum's research interests?

The research interests of Joseph L Witztum are: Atherosclerosis, oxidation, oxidized LDL, oxidized phospholipids, hyperlipidemia

What is Joseph L Witztum's total number of citations?

Joseph L Witztum has 120,791 citations in total.